Saturday 17 October 2026
Export STRO’s income statement to Excel — free account
Sutro Biopharma, Inc.
STRO Healthcare Biotechnology
Sutro Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $102.5 million, up 65.2% from fiscal 2024. In the quarter to June 2026, revenue fell 84.6%, EPS fell 66.4% and free cash flow grew 14.6%, each against the same quarter a year earlier.
10.94
0.52
−4.54%
Follow STRO
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | — | 4 | 1 | 2 | 3 | 5 | 3 | 2 | 3 |
P/S ratio |
0.00 | 0.00 | 1.35 | 5.91 | 16.55 | 11.09 | 6.00 | 1.79 | 2.29 | 0.96 |
Altman Z-Score |
— | — | (0.05) | 0.67 | 6.60 | 3.12 | (0.30) | (0.65) | (3.81) | (9.58) |
P/FCF ratio |
0.00 | 0.00 | 4.67 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(4.19) | (13.54) | 3.29 | (0.70) | 8.32 | 1.26 | 0.07 | (0.09) | (7.04) | (22.06) |
Beneish M-Score |
— | 1.86 | (2.89) | 3.15 | (2.41) | 13.25 | (4.51) | (0.20) | (4.15) | (3.10) |
P/Operating CF |
(0.52) | (0.52) | (8.75) | (19.20) | (37.46) | (31.80) | (17.05) | 19.54 | (1.98) | (3.72) |
P/B ratio |
0.00 | 0.00 | 0.39 | 2.58 | 2.13 | 2.72 | 1.87 | 1.84 | 3.19 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.39 | 2.58 | 2.13 | 2.72 | 1.87 | 1.84 | 3.19 | 0.00 |
EV/Sales |
0.00 | 0.00 | (3.59) | 3.38 | 8.53 | 8.30 | 1.31 | (0.60) | (2.69) | (0.34) |
EV/EBITDA |
0.00 | 0.00 | 4.15 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 0.69 | 0.23 |
EV/Operating CF |
0.61 | 0.61 | (10.87) | (2.22) | (5.38) | (6.29) | 25.03 | 0.83 | 0.87 | 0.20 |
EV/FCF |
0.58 | 0.58 | (12.39) | (2.11) | (4.87) | (5.29) | (20.62) | 0.80 | 0.86 | 0.20 |
Quick Ratio |
0.96 | 0.74 | 5.68 | 3.77 | 12.63 | 5.04 | 5.13 | 4.39 | 2.47 | 1.94 |
Current Ratio |
0.99 | 0.80 | 5.76 | 3.90 | 12.78 | 5.24 | 5.31 | 4.50 | 2.60 | 2.01 |
Net Debt/EBITDA |
(6.44) | 0.53 | 5.71 | 2.07 | 5.18 | 1.90 | 2.57 | 4.06 | 1.32 | 0.92 |
Debt/Assets |
1.72% | 35.72% | 6.60% | 6.32% | 6.23% | 7.36% | 4.00% | 0.86% | 0.00% | 0.00% |
Debt/Equity |
0.10 | (2.24) | 0.11 | 0.10 | 0.07 | 0.10 | 0.08 | 0.03 | 0.00 | 0.00 |
Asset Turnover |
1.08 | 0.94 | 0.29 | 0.23 | 0.16 | 0.17 | 0.18 | 0.35 | 0.14 | 0.37 |
Operating CF/Net income |
(7.73) | 1.88 | (0.36) | 1.17 | 2.11 | 0.77 | (0.03) | 1.05 | 0.84 | 0.93 |
Capex/Depreciation |
(0.75) | (0.65) | (0.39) | (1.05) | (1.49) | (2.01) | (1.48) | 1.91 | 1.24 | (0.44) |
Interest Coverage |
5.43 | (27.97) | 128.36 | (12.75) | (17.88) | (31.41) | (38.54) | (7.99) | (7.67) | (4.14) |
| (1.70%) | 19.70% | (313.40%) | (48.62%) | (14.95%) | (36.11%) | (50.77%) | (58.25%) | (234.19%) | 435.02% | |
| 3.09% | (35.78%) | (26.76%) | (29.38%) | (11.67%) | (28.70%) | (31.86%) | (24.34%) | (53.02%) | (68.12%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (77.22%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
9.35% | (256.69%) | (19.15%) | (52.97%) | (8.89%) | (52.95%) | (38.30%) | (30.54%) | (99.07%) | (221.06%) |
Average Days of Receivables |
3.53 | 11.46 | 23.65 | 53.79 | 47.49 | 73.46 | 38.36 | 85.66 | 50.69 | 14.16 |
Research and Development Expense of Revenue |
72.91% | 105.60% | 141.24% | 153.53% | 180.14% | 168.71% | 202.40% | 117.36% | 406.24% | 162.38% |
Selling, General and Administrative Expense of Revenue |
24.81% | 31.65% | 55.65% | 76.26% | 86.18% | 90.50% | 87.86% | 40.71% | 78.10% | 40.02% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
1.62% | 2.69% | 7.48% | 24.13% | 27.89% | 37.56% | 38.81% | 16.20% | 39.79% | 13.67% |
Graham Net Nets |
6.84 | 6.84 | 2.28 | 0.28 | 0.45 | 0.19 | 0.40 | 0.37 | 0.00 | (1.58) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 88.94 |
Earnings Yield |
(5.20%) | (5.20%) | (68.23%) | (22.00%) | (3.96%) | (15.39%) | (29.55%) | (38.95%) | (164.13%) | (194.93%) |
Free Cash Flow Yield |
(959.93%) | (959.93%) | 21.42% | (27.13%) | (10.60%) | (14.14%) | (1.06%) | (42.16%) | (136.73%) | (181.98%) |
Revenue per Share |
1,464.00 | 1,154.93 | 66.71 | 18.61 | 13.12 | 13.42 | 13.36 | 25.55 | 8.02 | 12.06 |
Operating CF per Share |
(322.38) | (827.52) | 22.02 | (28.32) | (20.82) | (17.71) | 0.70 | (18.55) | (24.76) | (20.86) |
Capex per Share |
(107.30) | (74.02) | (2.70) | (1.52) | (2.19) | (3.32) | (1.55) | (0.72) | (0.40) | (0.20) |
Free Cash Flow per Share |
(429.68) | (901.54) | 19.32 | (29.84) | (23.00) | (21.03) | (0.85) | (19.27) | (25.16) | (21.06) |
Cash per Share |
1,164.73 | 491.52 | 355.08 | 51.34 | 113.02 | 42.92 | 65.90 | 62.43 | 40.96 | 16.64 |
Shareholders Equity per Share |
284.83 | (145.00) | 228.41 | 42.59 | 101.94 | 54.76 | 42.78 | 24.87 | 5.76 | (15.59) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
284.83 | (145.00) | 228.41 | 42.59 | 101.94 | 54.76 | 42.78 | 24.87 | 5.76 | (15.59) |
Free Cash Flow |
(17.53) | (40.39) | 11.13 | (68.50) | (74.93) | (97.00) | (4.31) | (115.93) | (194.64) | (178.93) |
Working Capital |
(0.49) | (6.33) | 173.52 | 95.60 | 348.59 | 176.78 | 286.61 | 327.80 | 211.42 | 75.79 |
Capital Expenditures |
(4.38) | (3.32) | (1.56) | (3.48) | (7.13) | (15.32) | (7.86) | (4.31) | (3.10) | (1.69) |
Net Current Asset Value |
(7.98) | (21.64) | 118.35 | 69.99 | 316.12 | 129.67 | 163.26 | 100.46 | 0.70 | (155.36) |
EV/EBIT |
0.00 | 0.00 | 3.70 | 0.00 | 0.00 | 0.00 | 0.00 | 1.04 | 0.70 | 0.22 |
Capex to Sales |
0.07 | 0.06 | 0.04 | 0.08 | 0.17 | 0.25 | 0.12 | 0.03 | 0.05 | 0.02 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.31 | 0.36 | 0.37 | 0.34 | 0.37 | 0.34 | 0.22 | (0.10) | (0.14) | 0.37 |
Cash ROIC |
(29.06%) | (134.24%) | 3.17% | (30.37%) | (10.34%) | (20.40%) | (0.76%) | (21.90%) | (53.84%) | (1,993.38%) |
Accounts Receivable Turnover |
54.28 | 47.02 | 18.68 | 9.73 | 7.21 | 6.87 | 6.92 | 7.12 | 2.78 | 16.28 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
1.10 | 1.10 | 2.06 | 4.39 | 5.93 | 9.01 | 9.79 | 21.60 | 22.35 | 6.30 |
Average Payables |
3.15 | 3.15 | 2.98 | 4.32 | 5.56 | 5.78 | 5.40 | 7.12 | 9.96 | 9.02 |
Average Assets |
55.13 | 55.02 | 131.95 | 189.75 | 275.24 | 367.76 | 374.18 | 438.84 | 428.97 | 280.52 |
Average Common Equity |
(99.84) | (99.94) | 11.27 | 114.66 | 214.92 | 292.31 | 234.81 | 183.35 | 97.12 | (43.93) |
Columns are period end dates